NHD Global
Continue from catalog navigation into editorial analysis, evidence records and quality-documentation guidance.
Showing 7–12 of 16 reviewed articles · Page 2 of 3
Survodutide is a dual glucagon-receptor and GLP-1-receptor agonist in clinical development. “Dual agonist” describes receptor pharmacology; it is not a certificate of…
Read source review →SYNCHRONIZE-1 is the largest published survodutide obesity trial to date. The useful evidence is in the complete denominator, estimand, placebo response and…
Read source review →A clean comparison of cagrilintide, semaglutide and the studied CagriSema combination, including 2025–2026 phase 3 records and limits on transferring evidence.
Read source review →A source-grounded guide to cagrilintide’s amylin-receptor pharmacology, phase 2 trial design and the boundary between single-agent and combination evidence.
Read source review →A 2026 evidence map separating published retatrutide phase 2 data, completed phase 3 study records, unposted results and regulatory status.
Read source review →A close reading of retatrutide’s GIP, GLP-1 and glucagon receptor pharmacology and the 48-week phase 2 obesity trial, including limitations and current…
Read source review →If a target is not listed, submit the sequence, scale and specification for a custom-project feasibility review.
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
